Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ALTECH BATTERIES LTD Capital/Financing Update 2018

Jun 12, 2018

64444_rns_2018-06-12_dc5abcb8-e9c2-4b9f-9647-fcfac82c1885.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

Rule
2.7,
3.10.3,
3.10.4,
3.10.5

**Appendix

3B**

ASX ANNOUNCEMENT AND MEDIA RELEASE

**New

issue
announcement, application
for
quotation
of
additional
securities and
agreement**

_Information
or
documents
not
available
now
must
be
given
to
ASX
as
soon
as
available.

Information
and documents
given
to
ASX
become
ASX’s
property
and
may
be
made
public._

Introduced
01/07/96
Origin:
Appendix
5
Amended
01/07/98,
01/09/99,
01/07/00,
30/09/01,
11/03/02,
01/01/03,
24/10/05,
01/08/12

13
June
2018

Name
of
entity

Altech
Chemicals
Limited

ABN 45
125
301
206

We
(the
entity)
give
ASX
the
following
information.

**Part

1
-­‐
All
issues**


You must complete the relevant sections (attach sheets if there is not enough space).

You must complete the relevant sections (attach sheets if there is not enough space).
1 +Class of+securities issued or to be Performance Rights
issued
2 Number of+securities issued or to be
issued
(if
known)
or
maximum
22,000,000 Performance Rights
number which may be issued
3 Principal terms of the+securities (eg, Performance
Rights
were
issued
for nil
if options, exercise price and expiry
date; if partly paid+securities, the
consideration and are subject to various vesting
conditions. Upon vesting, each Performance
amount outstanding and due dates for Right converts to one fully paid ordinary share
payment; if+convertible securities,
the conversion price and dates for
conversion)
of the Company; there is no exercise price
payable upon converson.

4 Do
the[+] securities
rank
equally
in
all Performance
Rights
will
not
be
quoted
and
upon respects
from
the
date
of
allotment exercise,
the
issued
ordinary
shares
will
rank
pari
pasu with
an
existing[+] class
of
quoted with
all
other
fully
paid
ordinary
shares. +securities? If
the
additional
securities
do
not
rank equally,
please
state: • the
date
from
which
they
do

  • the
    extent
    to
    which
    they
    participate for
    the
    next
    dividend,
    (in
    the
    case
    of a
    trust,
    distribution)
    or
    interest payment
Performance Rights will not be quoted and upon
exercise, the issued ordinary shares will rank pari pasu
with all other fully paid ordinary shares.
• the extent to which they do not
rank equally, other than in relation
to the next dividend, distribution or
interest payment


5
Issue price or consideration



6
Purpose of the issue
(If issued as consideration for the
acquisition of assets, clearly identify
those assets)





6a
Is the entity an+eligible entity that has
obtained
security
holder
approval
under rule 7.1A?

If Yes, complete sections 6b – 6h_in_
relation to the+securities the subject of
this Appendix 3B, and comply with
section 6i


6b
The
date
the
security
holder
resolution under rule 7.1A was passed


6c
Number of+securities issued without
security holder approval under rule 7.1


6d Number
of
+securities
issued
with
security holder approval under rule 7.1A


6e Number of
+securities issued with
security holder approval under rule 7.3,
or another specific security holder
approval (specify date of meeting)
Performance Rights are issued for nil consideration

15,000,000 Performance Rights issued to Directors of
the Company pursuant to Shareholder Approval
obtained in General Meeting on 12-June-2018. 7,000,000
Performance Rights issued to various employees
pursuant to the Company’s Performance Rights Plan
approved by shareholders in General Meeting on 12-
June-2018..
No
n/a
nil
nil
nil
6f
Number of securities issued under an
exception in rule 7.2


6g
If securities issued under rule 7.1A, was
issue price at least 75% of 15 day VWAP
as calculated under rule 7.1A.3? Include
the issue date and both values. Include
the source of the VWAP calculation.


6h If securities were issued under rule 7.1A
for non-cash consideration, state date
on which valuation of consideration
was
released
to
ASX
Market
Announcements


6i
Calculate the entity’s remaining issue
capacity under rule 7.1 and rule 7.1A –
complete Annexure 1 and release to
ASX Market Announcements


7
Dates of entering
+securities into
uncertificated holdings or despatch of
certificates






8
Number and+class of all+securities
quoted on ASX (_including_the securities
in section 2 if applicable)







9
Number and+class of all+securities
not quoted on ASX (_including_the
securities in section 2 if applicable)





10
Dividend policy (in the case of a
trust, distribution policy) on the
increased capital (interests)

n/a
n/a
n/a
7.1: 63,981,081
7.1A: -
12 June 2018
Number ~~+~~Class
426,540,542
Ordinary Shares
Number +Class
12,200,000
20,000,000

10,500,000
Performance Rights: Employees
& Consultants
Performance Rights: Managing
Director
Performance Rights: Directors
n/a

**Part

2
-­‐
Bonus
issue
or
pro
rata
issue**

11
Is security holder approval required?



12
Is the issue renounceable or non-
renounceable?


13
Ratio in which the+securities will be
offered


14
+Class of+securities to which the offer
relates


15
+Record
date
to
determine
entitlements


16
Will holdings on different registers
(or subregisters) be aggregated for
calculating entitlements?


17
Policy for deciding entitlements in
relation to fractions




18 Names of countries in which the
entity has+security holders who will
not be sent new issue documents
Note: Security holders must be told how their
entitlements are to be dealt with.
Cross reference: rule 7.7.




19
Closing date for receipt of
acceptances or renunciations


20
Names of any underwriters


21
Amount of any underwriting fee or
commission


22
Names of any brokers to the issue



23
Fee or commission payable to the
broker to the issue


24
Amount of any handling fee payable
to brokers who lodge acceptances or
renunciations on behalf of+security
holders
  • 25 If
    the
    issue
    is
    contingent
    on[+] security holders’
    approval,
    the
    date
    of
    the meeting

  • 26 Date
    entitlement
    and
    acceptance form
    and
    prospectus
    or
    Product Disclosure
    Statement
    will
    be
    sent
    to persons
    entitled

  • 27 If
    the
    entity
    has
    issued
    options,
    and the
    terms
    entitle
    option
    holders
    to participate
    on
    exercise,
    the
    date
    on which
    notices
    will
    be
    sent
    to
    option holders

  • 28 Date
    rights
    trading
    will
    begin
    (if applicable)

  • 29 Date
    rights
    trading
    will
    end
    (if applicable)

  • 30 How
    do[+] security
    holders
    sell
    their entitlements in
    full
    through
    a
    broker?

  • 31 How
    do[+] security
    holders
    sell part of their
    entitlements
    through
    a
    broker and
    accept
    for
    the
    balance?

  • 32 How
    do[+] security
    holders
    dispose
    of their
    entitlements
    (except
    by
    sale through
    a
    broker)?

  • 33 +Despatch
    date

**Part

3
-­‐
Quotation
of
securities**

You
need
only
complete
this
section
if
you
are
applying
for
quotation
of
securities

34 Type of securities

(a)

(b)
(tick one)



Securities described in Part 1

All other securities
Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid,
employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible
securities

**Entities

that
have
ticked
box
34(a)**

**Additional

securities
forming
a
new
class
of
securities**

Tick
to
indicate
you
are
providing
the
information
or documents

  • 35 If
    the[+] securities
    are[+] equity
    securities,
    the
    names
    of
    the
    20
    largest
    holders
    of
    the additional[+] securities,
    and
    the
    number
    and
    percentage
    of
    additional[+] securities held
    by
    those
    holders

  • 36 If
    the[+] securities
    are[+] equity
    securities,
    a
    distribution
    schedule
    of
    the
    additional +securities
    setting
    out
    the
    number
    of
    holders
    in
    the
    categories

  • 1
    -­‐
    1,000

  • 1,001
    -­‐
    5,000

  • 5,001
    -­‐
    10,000 10,001
    -­‐
    100,000

  • 100,001
    and
    over

  • 37 A
    copy
    of
    any
    trust
    deed
    for
    the
    additional[+] securities

**Entities

that
have
ticked
box
34(b)**

38
Number of securities for which
+quotation is sought



39
Class of
+securities for which
quotation is sought



40
Do the+securities rank equally in
all respects from the date of
allotment with an existing+class
of quoted+securities?

If the additional securities do not
rank equally, please state:
• the date from which they do
• the extent to which they
participate
for
the
next
dividend, (in the case of a
trust, distribution) or interest
payment
• the extent to which they do
not rank equally, other than in
relation to the next dividend,
distribution
or
interest
payment


41
Reason for request for quotation
now
Example: In the case of restricted securities, end
of restriction period

(if issued upon conversion of
another security, clearly identify
that other security)

Number +Class 42 Number and +class of all +securities quoted on ASX ( including the
securities
in
clause 38)

**Quotation

agreement**

  • 1 +Quotation
    of
    our
    additional +securities
    is
    in
    ASX’s
    absolute
    discretion.
    ASX may
    quote
    the[+] securities
    on
    any
    conditions
    it
    decides.

  • 2 We
    warrant
    the
    following
    to
    ASX.

  • The
    issue
    of
    the[+] securities
    to
    be
    quoted
    complies
    with
    the
    law
    and
    is not
    for
    an
    illegal
    purpose.

  • There
    is
    no
    reason
    why
    those[+] securities
    should
    not
    be
    granted + quotation.

  • An
    offer
    of
    the[+] securities
    for
    sale
    within
    12
    months
    after
    their
    issue will
    not
    require
    disclosure
    under
    section
    707(3)
    or
    section
    1012C(6)
    of the
    Corporations
    Act.

Note:
An
entity
may
need
to
obtain
appropriate
warranties
from
subscribers
for
the
securities
in
order
to
be able
to
give
this
warranty

  • Section
    724
    or
    section
    1016E
    of
    the
    Corporations
    Act
    does
    not
    apply
    to any
    applications
    received
    by
    us
    in
    relation
    to
    any[+] securities
    to
    be quoted
    and
    that
    no-­‐one
    has
    any
    right
    to
    return
    any[+] securities
    to
    be quoted
    under
    sections
    737,
    738
    or
    1016F
    of
    the
    Corporations
    Act
    at
    the time
    that
    we
    request
    that
    the[+] securities
    be
    quoted.

  • If
    we
    are
    a
    trust,
    we
    warrant
    that
    no
    person
    has
    the
    right
    to
    return
    the +securities
    to
    be
    quoted
    under
    section
    1019B
    of
    the
    Corporations
    Act
    at the
    time
    that
    we
    request
    that
    the[+] securities
    be
    quoted.

  • 3 We
    will
    indemnify
    ASX
    to
    the
    fullest
    extent
    permitted
    by
    law
    in
    respect
    of
    any claim,
    action
    or
    expense
    arising
    from
    or
    connected
    with
    any
    breach
    of
    the warranties
    in
    this
    agreement.

  • 4 We
    give
    ASX
    the
    information
    and
    documents
    required
    by
    this
    form.

If
any information
or
document
not
available
now,
will
give
it
to
ASX
before +quotation
of
the +securities
begins.
We
acknowledge
that
ASX
is
relying
on the
information
and
documents.
We
warrant
that
they
are
(will
be)
true
and complete.

Sign
here: Date:
13
June
2018
( ~~Director/~~ Company
Secretary) Print
name: Shane
Volk

==
==
==
==
==

  • See
    chapter
    19
    for
    defined
    terms.

01/08/2012

Appendix
3B
Page
8

**Appendix

3B

Annexure
1**

Calculation
of
placement
capacity
under
rule
7.1
and rule
7.1A
for[+] eligible
entities

Introduced
01/08/12

**Part

1**

Rule 7.1 – Issues exceeding 15% of capital

Step 1: Calculate “A”, the base figure from which the placement capacity is calculated

==> picture [420 x 427] intentionally omitted <==

----- Start of picture text -----

Insert number of fully paid ordinary 297,324,057
securities on issue 12 months before date
of issue or agreement to issue
1,162,979 (12-7-17 Placement approved by
Add the following:
shareholders)
• Number of fully paid ordinary securities 44,118,337 (1-11-17 Placement approved by
shareholders)
issued in that 12 month period under an
exception in rule 7.2 21,824,224 (1-11-17 Placement approved by
shareholders)
• Number of fully paid ordinary securities 37,822,369 (11-12-17 Placement approved
issued in that 12 month period with by shareholders)
shareholder approval
7,142,857 (28-12-17 Placement approved
by shareholders)
• Number of partly paid ordinary
2,811,432 (1-12-17 Placement approved by
securities that became fully paid in that
shareholders)
12 month period
14,334,287 (3-1-18 Placement approved by
Note: shareholders)
• Include only ordinary securities here –
other classes of equity securities cannot
be added
• Include here (if applicable) the securities
the subject of the Appendix 3B to which
this form is annexed
• It may be useful to set out issues of
securities on different dates as separate
line items
Subtract the number of fully paid ordinary Nil
securities cancelled during that 12 month
period
“A” 426,540,542
----- End of picture text -----

  • See
    chapter
    19
    for
    defined
    terms.

01/08/2012

Appendix
3B
Page
9

==> picture [415 x 647] intentionally omitted <==

----- Start of picture text -----

Step 2: Calculate 15% of “A”
“B” 0.15
[Note: this value cannot be changed]
Multiply “A” by 0.15 63,981,081
Step 3: Calculate “C”, the amount of placement capacity under rule 7.1
that has already been used
Insert number of equity securities issued or
agreed to be issued in that 12 month period
not counting those issued:
• Under an exception in rule 7.2
• Under rule 7.1A
• With security holder approval under rule
7.1 or rule 7.4
Note:
• This applies to equity securities, unless
specifically excluded – not just ordinary
securities
• Include here (if applicable) the securities
the subject of the Appendix 3B to which
this form is annexed
• It may be useful to set out issues of
securities on different dates as separate
line items
“C” -
Step 4: Subtract “C” from [“A” x “B”] to calculate remaining
placement capacity under rule 7.1
“A” x 0.15 63,981,081
Note: number must be same as shown in
Step 2
Subtract “C” -
Note: number must be same as shown in
Step 3
Total [“A” x 0.15] – “C” 63,981,081
placement capacity under rule 7.1]
[Note: this is the remaining placement
capacity under rule 7.1]
----- End of picture text -----

  • See
    chapter
    19
    for
    defined
    terms.

01/08/2012

Appendix
3B
Page
10

==> picture [415 x 519] intentionally omitted <==

----- Start of picture text -----

Part 2
Rule 7.1A – Additional placement capacity for eligible entities
Step 1: Calculate “A”, the base figure from which the placement
capacity is calculated
“A”
Note: number must be same as shown in
Step 1 of Part 1
Step 2: Calculate 10% of “A”
“D” 0.10
Note: this value cannot be changed
Multiply “A” by 0.10
Step 3: Calculate “E”, the amount of placement capacity under rule
7.1A that has already been used
Insert number of equity securities issued or
agreed to be issued in that 12 month period
under rule 7.1A
Notes:
• This applies to equity securities – not
just ordinary securities
• Include here – if applicable – the
securities the subject of the Appendix
3B to which this form is annexed
• Do not include equity securities issued
under rule 7.1 (they must be dealt with
in Part 1), or for which specific security
holder approval has been obtained
• It may be useful to set out issues of
securities on different dates as separate
line items
“E”
----- End of picture text -----

  • See
    chapter
    19
    for
    defined
    terms.

01/08/2012

Appendix
3B
Page
11

Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A

Step 4: Subtract “E” from [“A” x “D”] to calculate remaining
placement capacity under rule 7.1A
Step 4: Subtract “E” from [“A” x “D”] to calculate remaining
placement capacity under rule 7.1A
“A” x 0.10
Note: number must be same as shown in
Step 2
Subtract“E”
Note: number must be same as shown in
Step 3
Total[“A” x 0.10] – “E” Note: this is the remaining placement
capacity under rule 7.1A


  • See
    chapter
    19
    for
    defined
    terms.

01/08/2012

Appendix
3B
Page
12